Communiqués Mendus AB

Actions

IMMU

SE0022239950

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 17/07/2026			Varia. 5j.	Varia. 1 janv.
6,000 ^SEK	-0,83%		-12,02%	+7,14%

16/07	Mendus prépare une nouvelle étude sur la LMC avec un institut de recherche australien	FW
16/07	Mendus AB et le South Australian Health and Medical Research Institute annoncent une collaboration pour préparer l'essai Vital-TFR2 dans la leucémie myéloïde chronique	CI

Communiqués

16/07	Mendus announces collaboration with the South Australian Health and Medical Research Institute (SAHMRI) to support preparation of the VITAL-TFR2 trial in chronic myeloid leukemia (CML)	AQ
08/07	Mendus reports complete enrollment of the first stage of the VITAL-CML trial	AQ
23/06	Mendus AB (publ) has decided on directed issues of Class C shares and transfer of own ordinary shares	AQ
10/06	Mendus AB (publ) repurchases outstanding warrants from Fenja	AQ
02/06	Mendus reports long-term progression-free survival associated with broad immune activation in high-risk ovarian cancer	AQ
27/05	Mendus AB (publ) has resolved to transfer own shares	AQ
13/05	Preclinical data presented at CIMT confirm combination potential of vididencel with current and upcoming CML treatments	AQ
11/05	Mendus (Q1 review): CML Phase I Initiated	AQ
08/05	Report from the Annual General Meeting of Mendus AB (publ) on 8 May 2026	AQ
08/05	Mendus AB Interim Report January – March 2026	AQ
01/05	Invitation to presentation of Mendus' first quarter 2026 financial report and business update	AQ
21/04	Flerie’s portfolio company Mendus advances clinical program with first patient enrolled in phase 1b trial	AQ
21/04	Mendus announces first patient enrolled in the VITAL-CML trial	AQ
17/04	Mendus : Item 7b. The board's proposal regarding allocation of results	PU
17/04	Mendus publishes Annual Report for 2025	AQ
09/04	Mendus announces start of clinical program in CML	AQ
02/04	Mendus : Notice to AGM 2026	PU
02/04	Mendus : Power of Attorney form AGM 2026	PU
02/04	Mendus : Item 12. The board's proposal regarding payment of bonuses to employees in shares	PU
02/04	Mendus : Item 13. The board's proposal regarding authorization to transfer own ordinary shares	PU
02/04	Mendus : Item 14. The board's proposal regarding LTI 2026 2029	PU
02/04	Mendus : Item 15. The board's proposal regarding authorization to issue shares	PU
01/04	Notice of Annual General Meeting in Mendus AB (publ)	AQ
23/03	Mendus signs agreement with Olivia Newton-John Cancer Research Institute to expand clinical development of vididencel in AML	AQ
16/02	Mendus (Q4 review): CML a New Value Driver	AQ